search
Back to results

Jet or Vibrating Mesh Nebulisation for Secretion Management in ICU

Primary Purpose

Respiratory Failure, Critical Illness

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser
Intermittent nebulisation 0.9% saline Aerogen vibrating mesh Solo Nebuliser
Intermittent standard intermittent nebulisation of 0.9% saline Intersurgical Cirrus 2 self sealing Jet Nebuliser
Sponsored by
NHS Greater Glasgow and Clyde
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Respiratory Failure focused on measuring nebuliser, secretions

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patient aged 18-80 years at time of recruitment to study Ventilated via an endotracheal tube or tracheostomy with an HME filter in the circuit Secretion load defined as patient requiring suctioning at least 2 times in the 6 hours prior to recruitment Sputum viscosity with grades 1 to 3 pourability in the Qualitative Sputum Assessment tool Not yet received saline nebulisation in the 6 hours prior to recruitment Likely to be ventilated via an endotracheal tube or tracheostomy for at least 3 days in the opinion of the treating clinician Exclusion Criteria: Pregnancy Pulmonary embolus Heart Failure (NYHA Grade III/IV) Clinical evidence of frank pulmonary oedema Cardiovascular instability (systolic BP ≤75 or heart rate ≥140)

Sites / Locations

  • Queen Elizabeth University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser

Intermittent nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser

Intermittent standard nebulisation of 0.9% saline Intersurgical Cirrus 2 self sealing Jet Nebuliser

Arm Description

Continuous nebulization of 0.9% normal saline using the Aerogen Solo Nebuliser (50mls/24h continuous infusion using a syringe pump)

Intermittent nebulization of 0.9% normal saline using the Aerogen Solo Nebuliser (5mls 0.9% normal saline nebulised every 6 hours)

Intermittent standard nebulization of 0.9% normal saline using the Intersurgical Cirrus 2 self-sealing Jet Nebuliser ((5mls 0.9% normal saline nebulised every 6 hours)

Outcomes

Primary Outcome Measures

Pourability of respiratory secretions (The QSA score will assess quantity, quality/stickiness/density and colour/appearance of secretions and is described and validated in the literature3,4)
Pourability of respiratory secretions as assessed by the QSA (Qualitative Sputum Assessment) Tool 0-4. . As the QSA Tool score ranges from 1 to 4 in increments of 0.5, with 1 being the most pourable and 4 the least pourable. (The QSA score will assess quantity, quality/stickiness/density and colour/appearance of secretions and is described and validated Lopez-Vidriero MT, Charman J, Keal E, De Silva DJ, Reid L. Sputum viscosity: correlation with chemical and clinical features in chronic bronchitis. Thorax. 1973 Jul;28(4):401-8. PubMed ID: 4741442

Secondary Outcome Measures

Volume of secretions
Total volume in ml of secretions aspirated from the patient's airway at 1000 and 1600 each day
Work of breathing
Recorded by ventilator as pressure over volume curve for each breath in joules/min
Airway resistance
Recorded by the ventilator in cm H2O/L/sec at 1000 and 1600 each day
Number of number of additional nebulised doses of saline or other drugs administered during the study period
Number of nebulized drug doses of drugs administered excluding study drugs
Ease of sampling, in the opinion of the treating nurse
Qualitative assessment scale 1-10 . 1 very easy to sample-10 very difficult to obtain a sputum sample.
Frequency of requiring changing the HME filter
Number of HME(heat moisture exchange) filter changes in the previous 24-hour period
Length of time on ventilator
Total number of days ventilated
Length of stay in ICU
Length of stay in ICU in days
Mortality
Alive at 28 days- Yes/NO

Full Information

First Posted
October 19, 2022
Last Updated
January 31, 2023
Sponsor
NHS Greater Glasgow and Clyde
Collaborators
Aerogen
search

1. Study Identification

Unique Protocol Identification Number
NCT05635903
Brief Title
Jet or Vibrating Mesh Nebulisation for Secretion Management in ICU
Official Title
Can Continuous or Intermittent Normal Saline Nebulisation Via a Vibrating Mesh Nebuliser or Intermittent Normal Saline Via a Standard Jet Nebuliser Improve the Lung Physiology and Secretion Viscosity in Mechanically Ventilated Patients?
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 22, 2019 (Actual)
Primary Completion Date
December 22, 2023 (Anticipated)
Study Completion Date
December 22, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NHS Greater Glasgow and Clyde
Collaborators
Aerogen

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Critically unwell patients in Intensive Care have a decreased ability to effectively clear secretions. High secretion load is a major risk factor in the failure of tracheal extubation failure and the requirement for reintubation. Extubation failure is a predictor of poor outcome independent of the severity of the underlying illness. Nebulisation of isotonic saline can be employed to manage secretions by reducing the secretion viscosity and facilitating clearance of respiratory sections during tracheal suction. Standard jet nebulisers have been the mainstay of respiratory section management therapy in critical care since the early 1990s. A more recent development has been the vibrating mesh nebuliser. There is evidence of improved humidification and reduced water particle size and theoretically better transfer to the distal airways.
Detailed Description
1.2 Rationale The vibrating mesh nebuliser (Aerogen technology) may be superior to standard nebuliser technology. 1.3 Study hypothesis Improved secretion management with reduced tenacity of respiratory sections and potentially improved lung physiology secondary to improved humidification or reduced size of nebulised particles? 2. STUDY OBJECTIVES Primary Endpoint Pourability of respiratory secretions (As assessed by the Qualitative Sputum Assessment Tool) (The QSA score will assess quantity, quality/stickiness/density and colour/appearance of secretions and is described and validated in the literature3,4) Secondary endpoints Volume of secretions (increased or decreased may be beneficial) Work of breathing Airway resistance Number of number of additional nebulised doses of saline or other drugs administered during the study period Ease of sampling, in the opinion of treating nurse Frequency of requiring changing the HME(heat and moisture exchange) filter Length of time on ventilator Length of stay in ICU/HDU(Intensive care unit/high dependancy unit) ICU Mortality 3. STUDY DESIGN 3.1 Study Population A total of 60 patients will be recruited to the study. Each patient will be randomised to receive: Continuous nebulisation of 0.9% normal saline using the Aerogen Solo Nebuliser (50mls/24h via a syringe feed set) OR Intermittent nebulisation of 0.9% normal saline using the Aerogen Solo Nebuliser (5mls, 6 hourly) OR Intermittent standard nebulisation of 0.9% normal saline using the Intersurgical Cirrus 2 self-sealing Jet Nebuliser (5 mls, 6 hourly)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Failure, Critical Illness
Keywords
nebuliser, secretions

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser
Arm Type
Experimental
Arm Description
Continuous nebulization of 0.9% normal saline using the Aerogen Solo Nebuliser (50mls/24h continuous infusion using a syringe pump)
Arm Title
Intermittent nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser
Arm Type
Experimental
Arm Description
Intermittent nebulization of 0.9% normal saline using the Aerogen Solo Nebuliser (5mls 0.9% normal saline nebulised every 6 hours)
Arm Title
Intermittent standard nebulisation of 0.9% saline Intersurgical Cirrus 2 self sealing Jet Nebuliser
Arm Type
Active Comparator
Arm Description
Intermittent standard nebulization of 0.9% normal saline using the Intersurgical Cirrus 2 self-sealing Jet Nebuliser ((5mls 0.9% normal saline nebulised every 6 hours)
Intervention Type
Procedure
Intervention Name(s)
Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser
Intervention Description
Continuous nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser
Intervention Type
Procedure
Intervention Name(s)
Intermittent nebulisation 0.9% saline Aerogen vibrating mesh Solo Nebuliser
Intervention Description
Intermittent nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser
Intervention Type
Procedure
Intervention Name(s)
Intermittent standard intermittent nebulisation of 0.9% saline Intersurgical Cirrus 2 self sealing Jet Nebuliser
Intervention Description
standard intermittent nebulisation of 0.9% saline using the Intersurgical Cirrus 2 self-sealing Jet Nebuliser
Primary Outcome Measure Information:
Title
Pourability of respiratory secretions (The QSA score will assess quantity, quality/stickiness/density and colour/appearance of secretions and is described and validated in the literature3,4)
Description
Pourability of respiratory secretions as assessed by the QSA (Qualitative Sputum Assessment) Tool 0-4. . As the QSA Tool score ranges from 1 to 4 in increments of 0.5, with 1 being the most pourable and 4 the least pourable. (The QSA score will assess quantity, quality/stickiness/density and colour/appearance of secretions and is described and validated Lopez-Vidriero MT, Charman J, Keal E, De Silva DJ, Reid L. Sputum viscosity: correlation with chemical and clinical features in chronic bronchitis. Thorax. 1973 Jul;28(4):401-8. PubMed ID: 4741442
Time Frame
At 1000 and 1600 for 3 days
Secondary Outcome Measure Information:
Title
Volume of secretions
Description
Total volume in ml of secretions aspirated from the patient's airway at 1000 and 1600 each day
Time Frame
At 1000 and 1600 for 3 days
Title
Work of breathing
Description
Recorded by ventilator as pressure over volume curve for each breath in joules/min
Time Frame
At 1000 and 1600 for 3 days
Title
Airway resistance
Description
Recorded by the ventilator in cm H2O/L/sec at 1000 and 1600 each day
Time Frame
At 1000 and 1600 for 3 days
Title
Number of number of additional nebulised doses of saline or other drugs administered during the study period
Description
Number of nebulized drug doses of drugs administered excluding study drugs
Time Frame
Number of administer nebulised drugs per 24hour per
Title
Ease of sampling, in the opinion of the treating nurse
Description
Qualitative assessment scale 1-10 . 1 very easy to sample-10 very difficult to obtain a sputum sample.
Time Frame
At 1000 and 1600 for 3 days
Title
Frequency of requiring changing the HME filter
Description
Number of HME(heat moisture exchange) filter changes in the previous 24-hour period
Time Frame
Number of filters used in each 24 hour period for 3 days
Title
Length of time on ventilator
Description
Total number of days ventilated
Time Frame
1 years after admission to ICU/HDU(Intensive care unit/high dependance unit)
Title
Length of stay in ICU
Description
Length of stay in ICU in days
Time Frame
Number of day in ICU and HDU at Queen Elizabeth University hospital
Title
Mortality
Description
Alive at 28 days- Yes/NO
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient aged 18-80 years at time of recruitment to study Ventilated via an endotracheal tube or tracheostomy with an HME filter in the circuit Secretion load defined as patient requiring suctioning at least 2 times in the 6 hours prior to recruitment Sputum viscosity with grades 1 to 3 pourability in the Qualitative Sputum Assessment tool Not yet received saline nebulisation in the 6 hours prior to recruitment Likely to be ventilated via an endotracheal tube or tracheostomy for at least 3 days in the opinion of the treating clinician Exclusion Criteria: Pregnancy Pulmonary embolus Heart Failure (NYHA Grade III/IV) Clinical evidence of frank pulmonary oedema Cardiovascular instability (systolic BP ≤75 or heart rate ≥140)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
malcolm SIm, MBChB
Phone
01414523430
Email
malcolm.sim@ggc.scot.nhs.uk
First Name & Middle Initial & Last Name or Official Title & Degree
malcolm watson, MBCHB
Phone
01414523430
Email
malcolm.watson@ggc.scot.nhs.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Malcolm Sim, MBcHB
Organizational Affiliation
nhs GGC health board
Official's Role
Principal Investigator
Facility Information:
Facility Name
Queen Elizabeth University Hospital
City
Glasgow
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Malcolm Sim, MB ChB
Phone
01414523430
Email
malcolm.sim@ggc.scot.nhs.uk
First Name & Middle Initial & Last Name & Degree
Malcolm j watson, MBchB
Phone
01414523430
Email
mwatson@doctors.org.uk

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
23641924
Citation
Thille AW, Richard JC, Brochard L. The decision to extubate in the intensive care unit. Am J Respir Crit Care Med. 2013 Jun 15;187(12):1294-302. doi: 10.1164/rccm.201208-1523CI.
Results Reference
background
PubMed Identifier
30519901
Citation
Terzi N, Guerin C, Goncalves MR. What's new in management and clearing of airway secretions in ICU patients? It is time to focus on cough augmentation. Intensive Care Med. 2019 Jun;45(6):865-868. doi: 10.1007/s00134-018-5484-2. Epub 2018 Dec 5. No abstract available.
Results Reference
result
PubMed Identifier
30243304
Citation
Jaber S, Quintard H, Cinotti R, Asehnoune K, Arnal JM, Guitton C, Paugam-Burtz C, Abback P, Mekontso Dessap A, Lakhal K, Lasocki S, Plantefeve G, Claud B, Pottecher J, Corne P, Ichai C, Hajjej Z, Molinari N, Chanques G, Papazian L, Azoulay E, De Jong A. Risk factors and outcomes for airway failure versus non-airway failure in the intensive care unit: a multicenter observational study of 1514 extubation procedures. Crit Care. 2018 Sep 23;22(1):236. doi: 10.1186/s13054-018-2150-6.
Results Reference
result
PubMed Identifier
4647626
Citation
Keal EE, Reid L. Neuraminic acid content of sputum in chronic bronchitis. Thorax. 1972 Nov;27(6):643-53. doi: 10.1136/thx.27.6.643.
Results Reference
result
PubMed Identifier
4741442
Citation
Lopez-Vidriero MT, Charman J, Keal E, De Silva DJ, Reid L. Sputum viscosity: correlation with chemical and clinical features in chronic bronchitis. Thorax. 1973 Jul;28(4):401-8. doi: 10.1136/thx.28.4.401.
Results Reference
result
Citation
Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceutical Statistics 2005; 4(4): 287-291.
Results Reference
result

Learn more about this trial

Jet or Vibrating Mesh Nebulisation for Secretion Management in ICU

We'll reach out to this number within 24 hrs